Results 41 to 50 of about 440,184 (328)

Updates in the Treatment of Peripheral T-Cell Lymphomas

Journal of Experimental Pharmacology, 2021
Peripheral T-cell lymphomas (PTCLs) represent a heterogeneous group of rare hematologic malignancies accounting for less than 10% of non-Hodgkin lymphomas. The 2016 classification of World Health Organization recognized 29 different entities of PTCLs. These subgroups are characterized by different molecular and genetic patterns.
Vincent Ribrag, Khalil Saleh, Jean-Marie Michot   +2 more
openaire   +6 more sources

Multiple osteolytic primary peripheral T-cell bone lymphoma: the first case report

Journal of International Medical Research, 2021
Peripheral T-cell lymphoma accounts for about 10% of all cases of non-Hodgkin’s lymphoma. However, less than 5% of patients with non-Hodgkin’s lymphoma present with hypercalcaemia as the initial symptom, and less than 1% present with primary bone lesions.
Chen Li, Weiguo Wang, Lingyun Xu, Dingyun Zheng, Miao Zhang, Qin Zhang, Xiaoqian Wu, Yue Yao, Wenyue Huang, Xue Li, Peipei Ying, Xiuxiu Wang, Liu Shang, Yuhu Feng   +13 more
doaj   +1 more source

Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project [PDF]

, 2011
The International Peripheral T-cell Lymphoma Project is a collaborative effort to better understand peripheral T-cell lymphoma (PTCL). A total of 22 institutions submitted clinical and pathologic material on 1314 cases.
Armitage J.O., Au W.Y., Berger F., Campo E., Coiffier B., Federico M., Gascoyne R.D., Harris N.L., Holte H., Jaffe E.S., Kim W.S., MacLennan K.A., Nakamura S., Nathwani B., Pileri S., Rüdiger T., Savage K.J., Tobinai K., Vose J.M., Weisenburger D.D., Zinzani P.L.   +20 more
core   +1 more source

Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707

Haematologica, 2017
The standard CHOP therapy for peripheral T-cell lymphoma has resulted in unsatisfactory outcomes and it is still not clear what is the optimal front-line therapy.
Yoshinobu Maeda, Hisakazu Nishimori, Isao Yoshida, Yasushi Hiramatsu, Masatoshi Uno, Yasufumi Masaki, Kazutaka Sunami, Taro Masunari, Yuichiro Nawa, Hiromichi Yamane, Hiroshi Gomyo, Tsutomu Takahashi, Tomofumi Yano, Keitaro Matsuo, Koichi Ohshima, Shigeo Nakamura, Tadashi Yoshino, Mitsune Tanimoto   +17 more
doaj   +1 more source

CD20 Positive T Cell Lymphoma Involvement of Skin [PDF]

, 2011
CD20 positive T cell lymphoma is a rare condition that is associated with the coexpressions of CD20 and T cell markers, such as, CD3, CD5, or UCHL-1. Positivity for CD20 in this tumor represents an aberrant immunophenotype, but the presence of monoclonal
Balmer, Balmer, Buckner, Cerny, Gill, Hamilton-Dutoit, Jin Woo Hong, Ki Ho Kim, Ki Hoon Song, Ki Yeol Lee, Magro, Medeiros, Mohrmann, Murayama, Norton, Oshima, Quintanilla-Martinez, Rahemtullah, Sen, Su Young Jeon, Sun, Tarkowski, Venizelos, Warzynski, Xiao, Yao, Yokose, Young Hun Kim   +27 more
core   +2 more sources

The inducible T-cell co-stimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivation

Haematologica, 2010
Background T follicular helper (TFH) cells reside in the light zone of germinal centers and are considered the cell of origin of angioimmunoblastic T-cell lymphoma.
Teresa Marafioti, Jennifer C. Paterson, Erica Ballabio, Andreas Chott, Yasodha Natkunam, Manuel Rodriguez-Justo, Anne Plonquet, Socorro M. Rodriguez-Pinilla, Wolfram Klapper, Martin-L. Hansmann, Stefano A. Pileri, Peter G. Isaacson, Harald Stein, Miguel A. Piris, David Y. Mason, Philippe Gaulard   +15 more
doaj   +1 more source

Burrowing through the heterogeneity: Review of mouse models of PTCL-NOS [PDF]

, 2016
Currently, there are 19 different peripheral T-cell lymphoma (PTCL) entities recognized by the World Health Organization; however, ~70% of PTCL diagnoses fall within one of three subtypes [i.e., peripheral T-cell lymphoma not otherwise specified (PTCL ...
Agostinelli, Basakran, Beachy, Boman, Bonnet, Bug, Canela, Chan, Chu, Cook, Cornal, Costello, Cotta, Dick, Dierks, Dutta, Feldman, Felsher, Friend, Ishiguro, Kuppers, Morrow, Munoz, Nagel, Orchansky, Ortega, Park, Pattengale, Pechloff, Roberts, Rohr, Rudiger, Savage, Sentman, Soulier, Teramoto, Toya, Wang, Wang, Warner, Yan   +40 more
core   +3 more sources

Prognostic Markers in Peripheral T-Cell Lymphoma [PDF]

Current Hematologic Malignancy Reports, 2010
Based on their own experience and knowledge of the literature, the authors review the pathobiological characteristics of peripheral T-cell lymphomas (PTCLs), focusing on the available prognostic indicators. The International Prognostic Index (IPI), which is based on age, performance status, lactate dehydrogenase [LDH], stage, and extranodal involvement,
PICCALUGA, PIER PAOLO, AGOSTINELLI, CLAUDIO, GAZZOLA, ANNA, Mannu C, BACCI, FRANCESCO, SABATTINI, ELENA, PILERI, STEFANO   +6 more
openaire   +3 more sources

Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience [PDF]

, 2007
OBJECTIVES: Angioimmunoblastic T-cell lymphoma (AIL) is a rare lymphoma with a poor prognosis and no standard treatment. Here, we report our experiences with 19 patients treated with high-dose chemotherapy and autologous stem cell transplantation (HDC ...
Albo, C. (Carmen), Arranz, R. (R.), Bendandi, M. (Maurizio), Bergua, J. (J.), Caballero, M.D. (M.D.), Carrera, D. (D,), Cañigral, G. (G.), Conde, E. (Eulogio), Fernandez, P. (Pascual), Gandarillas, M. (M.), Garcia, J. (Juan Carlos), Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea (GEL-TAMO), Gutierrez, A. (Antonio), Leon, A. (Angel), Moraleda, J. (José), Morales, A. (Alfonso), Ojanguren, J. (Jesús), Ribera, J.M. (José María), Rodriguez, J. (José), Sureda, A. (Anna)   +19 more
core   +1 more source

Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China

Journal of Hematology & Oncology, 2017
The efficacy and safety of chidamide, a new subtype-selective histone deacetylase (HDAC) inhibitor, have been demonstrated in a pivotal phase II clinical trial, and chidamide has been approved by the China Food and Drug Administration (CFDA) as a ...
Yuankai Shi, B. Jia, W. Xu, Wenyu Li, Ting Liu, Peng Liu, Weili Zhao, Huilai Zhang, Xiuhua Sun, Haiyan Yang, Xi Zhang, Jie Jin, Z. Jin, Zhiming Li, L. Qiu, M. Dong, Xiao-bing Huang, Yi Luo, Xiaodong Wang, Xin Wang, Jian-qiu Wu, Jingyan Xu, Pingyong Yi, Jianfeng Zhou, Hong-tao He, Lin Liu, Jianzhen Shen, Xiaoqiong Tang, Jinghua Wang, Jianmin Yang, Q. Zeng, Zhihui Zhang, Z. Cai, Xiequn Chen, K. Ding, M. Hou, Huiqiang Huang, Xiaoling Li, R. Liang, Qi-fa Liu, Yuqin Song, H. Su, Yu-huan Gao, Lihong Liu, Jianmin Luo, L. Su, Zimin Sun, H. Tan, Hua-qing Wang, Jingwen Wang, Shuye Wang, Hongyu Zhang, Xiao-hong Zhang, Dao-bin Zhou, O. Bai, Gang Wu, Liling Zhang, Yizhuo Zhang   +57 more
semanticscholar   +1 more source